Trial · NCT05082571
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Change in Hemoglobin (Hb) Values Between Baseline and the Primary Evaluation Period (Average Hb From Weeks 21 to 28) | Baseline; Weeks 21 to 28 | |
| Secondary | Time to Achieve Hb Levels of ≥10.0 grams/deciliters (g/dL) | Up to Week 52 | |
| Secondary | Number of Participants With Mean Hb Values Within the Target Range During the Primary Evaluation Period | From Week 21 to Week 28 | |
| Secondary | Number of Participants With Mean Hb Values Within the Target Range During the Extension Period | From Week 29 to Week 52 | |
| Secondary | Number of Participants With Treatment-emergent Adverse Events and who Discontinued From the Study due to Adverse Events | Up to Week 56 | |
| Secondary | Maximum Observed Plasma Concentration (Cmax) of Vadadustat and its Metabolites | Pre-dose and post-dose at intermediate time points up to 28 weeks | |
| Secondary | Time to Reach Cmax (Tmax) of Vadadustat and its Metabolites | Pre-dose and post-dose at intermediate time points up to 28 weeks | |
| Secondary | Area Under the Plasma Concentration-Time Curve From 0 to Last Quantifiable Concentration (AUC 0-t) of Vadadustat and its Metabolites | Pre-dose and post-dose at intermediate time points up to 28 weeks | |
| Secondary | Terminal Elimination Half-Life (t1/2) of Vadadustat and its Metabolites | Pre-dose and post-dose at intermediate time points up to 28 weeks | |
| Secondary | Change From Baseline in Serum Erythropoietin (EPO) | Pre-dose and post-dose at intermediate time points up to 28 weeks | |
| Secondary | Change From Baseline in Reticulocyte Count | Pre-dose and post-dose at intermediate time points up to 28 weeks | |
| Secondary | Change From Baseline in Hb levels | Pre-dose and post-dose at intermediate time points up to 28 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05082571/registered